Cite

    Arndt Vogel et al.. “Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.” Lancet gastroenterology and hepatology, vol. 6, 2021, pp. 649–658. http://access.bl.uk/ark:/81055/vdc_100133937732.0x00000c